Studies have shown that rebamipide can fight the damaging effects of
NSAIDs on the
GIT mucosa,[5] and more recently, the small intestine, but not for naproxen-induced gastric damage.[6]
Availability
Rebamipide is used in a number of Asian countries including
Japan (marketed as Mucosta),
South Korea,
China[7] and
India (where it is marketed under the trade name Rebagen). It is also approved in
Russia under the brand name Rebagit.[8]
References
^Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A (September 1998). "Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing". Digestive Diseases and Sciences. 43 (9 Suppl): 5S–13S.
PMID9753220.
^Arakawa T, Watanabe T, Fukuda T, Yamasaki K, Kobayashi K (November 1995). "Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine". Digestive Diseases and Sciences. 40 (11): 2469–72.
doi:
10.1007/bf02063257.
PMID7587834.
S2CID22807270.
^Tarnawski AS, Chai J, Pai R, Chiou SK (February 2004). "Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?". Digestive Diseases and Sciences. 49 (2): 202–9.
doi:
10.1023/b:ddas.0000017439.60943.5c.
PMID15104358.
S2CID31756608.
^Zhang S, Qing Q, Bai Y, Mao H, Zhu W, Chen Q, Zhang Y, Chen Y (July 2013). "Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis". Digestive Diseases and Sciences. 58 (7): 1991–2000.
doi:
10.1007/s10620-013-2606-0.
PMID23456504.
S2CID4887031.